Latest Intellectual Property News

Mesoblast has refinanced its senior debt with a new US$125 million, five-year credit facility that lowers borrowing costs and preserves key assets, positioning the company for strategic growth.

Aeeris Ltd has received a $506,992.50 refundable R&D tax incentive for FY25, fueling advancements in its proprietary Australian Weather And Risk Environment (AWARE) system and AI-driven forecasting tools.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

Scout Security outlines a bold transformation with the acquisition of Roo Inc., expansion into insuretech, and a pivot to AI-driven smart security solutions, positioning itself for accelerated growth and profitability.

EPX Limited has secured Wattwatchers Pty Limited through a Deed of Company Arrangement, backed by a $2.14 million placement and a Share Purchase Plan to raise additional funds. This strategic move enhances EPX’s energy monitoring capabilities and recurring revenue streams.

Dotz Nano Limited has raised approximately A$2 million through a private placement, reinforcing its position in the emerging carbon capture market with fresh capital and new investors.

PlaySide Studios is gearing up for a pivotal 2026 with its highly anticipated game launch and strategic expansion into the MENAT region, underpinned by strong cost savings and leadership hires.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Alexium International Group Limited has announced a pro rata non-renounceable rights issue to raise approximately AUD 6.77 million, primarily to repay shareholder loans and finance the acquisition of Microtek Laboratories' microencapsulation business.